Companies · Pharmaceuticals

Neonc Technologies, Inc.

WEST HOLLYWOOD · Pharmaceuticals

Diligence memoA one-page analyst read on Neonc Technologies, Inc. — recommendation, valuation, rhythm, risks.
$20.1M
Total raised · real
2
Rounds
1.0×
Latest step-up
Top 34%
Sector rank · raised
Series B
Latest stage · inferred · Sat Jul 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Neonc Technologies, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.00× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era.
  • Within the normal band (100% of peer median) for its niche.
Dormant
  • Last raise 9.0 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Neonc Technologies, Inc. is one of 1610 Pharmaceuticals companies tracked from WEST HOLLYWOOD. By capital raised it ranks mid-pack (ahead of 67% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2009
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BPre-Seed · 2012-06-04 Raised $150K (real) Modeled valuation $7.1M (est)$150K$7.1MPre-Seed2012Series B · 2017-07-01 Raised $20M (real) Modeled valuation $680M (est)$20M$680MSeries B2017Series B · 2017-07-01 Raised $20M (real) Modeled valuation $680M (est)$20M$680MSeries B2017+$20M+$20MCumulative $40M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$150K · 2012
Series B$20.0M · 2017no Seed / Series A on file
Series B extension$20.0M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$680.1M
Base estimate est.
$42.0M
Conservative case
$2.6B
Upside case
$111.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $7.1M · 2012-06-042012Series B · modeled $680.1M · 2017-07-01Series B · modeled $680.1M · 2017-07-012017
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
57%
Survival probability
38% low · 70% high
1.49×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
9.0 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
30 mo
Avg between rounds
$4.0M/yr
Capital velocity
14.1 yr
On record since
2012
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.5× above median
This company$20.1M
Sector median$8.1M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.1× above median
This company$20.0M
Sector median$18.0M
Modeled value — vs sector median (estimate, all stages) 8.9× above median
This company$680.1M
Sector median$76.1M

Raised more than 67% of sector peers (real $). Modeled value above 85% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #20 of 40.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)LP Investors, LLC · Series B Raised $40.0M · modeled $1.4B (est)GigaGen, Inc. · Series B Raised $36.1M · modeled $1.2B (est)Vitality Biopharma, Inc. · Series B Raised $39.5M · modeled $1.2B (est)Madrigal Pharmaceuticals, Inc. · Series B Raised $35.0M · modeled $1.2B (est)Slayback Pharma Ltd Liability Co · Series B Raised $35.0M · modeled $1.2B (est)X4 Pharmaceuticals, Inc. · Series B Raised $73.2M · modeled $1.2B (est)Lumos Pharma, Inc. · Series B Raised $53.5M · modeled $1.2B (est)Innovate Biopharmaceuticals Inc. · Series B Raised $42.7M · modeled $1.1B (est)SteadyMed Ltd. · Series B Raised $51.3M · modeled $1.0B (est)Stargazer Pharmaceuticals, Inc. · Series B Raised $28.5M · modeled $967.8M (est)St Renatus Llc · Series B Raised $33.1M · modeled $884.1M (est)Bellerophon Therapeutics, Inc. · Series B Raised $25.0M · modeled $796.9M (est)Neonc Technologies, Inc. (this company) Raised $20.1M · modeled $680.1M (est)Neonc Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
LP Investors, LLCSeries B$40.0M$1.4B2.00×
GigaGen, Inc.Series B$36.1M$1.2B1.81×
Vitality Biopharma, Inc.Series B$39.5M$1.2B1.80×
Madrigal Pharmaceuticals, Inc.Series B$35.0M$1.2B1.75×
Slayback Pharma Ltd Liability CoSeries B$35.0M$1.2B1.75×
X4 Pharmaceuticals, Inc.Series B$73.2M$1.2B1.75×
Lumos Pharma, Inc.Series B$53.5M$1.2B1.70×
Innovate Biopharmaceuticals Inc.Series B$42.7M$1.1B1.64×
SteadyMed Ltd.Series B$51.3M$1.0B1.50×
Stargazer Pharmaceuticals, Inc.Series B$28.5M$967.8M1.42×
St Renatus LlcSeries B$33.1M$884.1M1.30×
Bellerophon Therapeutics, Inc.Series B$25.0M$796.9M1.17×
Neonc Technologies, Inc. this companySeries B$20.1M$680.1M1.00×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$150K2012-06-04$833K$7.1M85%
Series B$20.0M2017-07-01$111.1M$680.1M90%
Series B$20.0M2017-07-01$111.1M$680.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$150K2012-06-04
    • First recorded raise — entered as Pre-Seed.
    • 6 investors on this round.
  2. Series B$20.0M2017-07-01
    • Raised again after 61 mo — slower than the ~13 mo sector norm.
    • Round 133.3× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 504).
  3. Series B$20.0M2017-07-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
Intelligence
2020 ~Q1
Modeled next raise · ~30mo cadence
$20.0M
Modeled next size est.range $20.0M$32.0M
1.0×
Last step-up
$4.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Thomas Chen4 other2017-07
Vincent Simmon1 other2017-07
Alan Chiang2017-07
Clovis Orlando Da Fonseca2017-07
Jim Walters2017-07
Matthew Lin2017-07
Patrick Walters2012-06
Vicki Shih2017-07
Registry & provenance

Neonc Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1478689
SEC CIK
2009
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Botanix Pharmaceuticals Ltd.PharmaceuticalsSeries B$20.0M$681.3Msame sector · same stage
CutisPharma, Inc.PharmaceuticalsSeries B$20.0M$680.1Msame sector · same stage
Fibrogen IncPharmaceuticalsSeries B$20.0M$680.1Msame sector · same stage
Stemtrix Corp.PharmaceuticalsSeries B$20.0M$242.1Msame sector · same stage
Tyme Technologies, Inc.PharmaceuticalsSeries B$20.0M$680.1Msame sector · same stage
Xenoport IncPharmaceuticalsSeries B$20.0M$680.1Msame sector · same stage
Alnara Pharmaceuticals IncPharmaceuticalsSeries B$20.0M$679.9Msame sector · same stage
Trillium Therapeutics Inc.PharmaceuticalsSeries B$20.0M$679.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Neonc Technologies Holdings, Inc.BiotechnologySeries C$51.8M90%
Neon Therapeutics, Inc.BiotechnologySeries D+$4.4B87%
Pharmaceutics International, Inc.PharmaceuticalsSeries D+$123.9M83%
Botanix Pharmaceuticals Ltd.PharmaceuticalsSeries B$681.3M81%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.0M81%
Cambridge Therapeutic Technologies, LLCPharmaceuticalsSeries A$185.8M81%
Eldec Pharmaceuticals, Inc.PharmaceuticalsPre-Seed$351K81%
Neurock Pharmaceuticals Inc.PharmaceuticalsSeries A$59.9M81%
Frequently asked
How much funding has Neonc Technologies, Inc. raised?
Neonc Technologies, Inc. has raised approximately $20.1M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Neonc Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for Neonc Technologies, Inc. is approximately $680.1M (modeled range $42.0M–$2.6B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Neonc Technologies, Inc. at?
Neonc Technologies, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Sat Jul 01.
What does Neonc Technologies, Inc. do and where is it based?
Neonc Technologies, Inc. operates in the Pharmaceuticals sector, based in WEST HOLLYWOOD.
Explore related

See where Neonc Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Neonc Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.